[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Legend Biotech Corp ADR (LEGN)

Legend Biotech Corp ADR (LEGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,187,719
  • Shares Outstanding, K 185,740
  • Annual Sales, $ 1,029 M
  • Annual Income, $ -296,800 K
  • EBIT $ -251 M
  • EBITDA $ -222 M
  • 60-Month Beta 0.35
  • Price/Sales 6.05
  • Price/Cash Flow N/A
  • Price/Book 5.34

Options Overview Details

View History
  • Implied Volatility 60.50% (+5.64%)
  • Historical Volatility 131.74%
  • IV Percentile 57%
  • IV Rank 22.29%
  • IV High 119.66% on 03/19/26
  • IV Low 43.54% on 11/14/25
  • Expected Move (DTE 27) 2.92 (10.47%)
  • Put/Call Vol Ratio 0.53
  • Today's Volume 5,013
  • Volume Avg (30-Day) 1,548
  • Put/Call OI Ratio 0.41
  • Today's Open Interest 23,750
  • Open Int (30-Day) 20,150
  • Expected Range 25.01 to 30.85

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.12
  • Number of Estimates 7
  • High Estimate $0.28
  • Low Estimate $-0.02
  • Prior Year $-0.34
  • Growth Rate Est. (year over year) +135.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
24.81 +12.58%
on 06/01/26
37.50 -25.52%
on 06/03/26
+0.95 (+3.52%)
since 05/18/26
3-Month
16.70 +67.25%
on 03/30/26
37.50 -25.52%
on 06/03/26
+9.72 (+53.38%)
since 03/18/26
52-Week
16.24 +71.98%
on 02/04/26
45.30 -38.34%
on 07/23/25
-6.96 (-19.95%)
since 06/18/25

Most Recent Stories

More News
Legend Biotech Corporation Announces Pricing of Public Offering

BRIDGEWATER, N.J., June 17, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech” or the “Company”), a global leader in cell therapy, today announced the pricing...

LEGN : 27.93 (-16.68%)
Legend Biotech Corporation Announces Proposed Public Offering 

BRIDGEWATER, N.J., June 17, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech” or the “Company”), a global leader in cell therapy, today announced that it has...

LEGN : 27.93 (-16.68%)
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Achieved 100% ORR and 83.3% CR rate at dose level 2 following a single infusion in patients with relapsed/refractory B-NHL in an ongoing Phase 1 study Single infusion of LB2501 generated dose-dependent...

LEGN : 27.93 (-16.68%)
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

 Achieved 100% ORR and 83.3% CR rate at dose level 2 following a single infusion in patients with relapsed/refractory B-NHL in an ongoing Phase 1 study Single infusion of LB2501 generated dose-dependent...

LEGN : 27.93 (-16.68%)
Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)

Promising Phase 1 data for LB2501, a potential first ‑ in ‑ class CD19/CD20 dual ‑ targeting in vivo CAR-T therapy, as an off-the-shelf, single-infusion treatment for B ‑ cell malignancies...

LEGN : 27.93 (-16.68%)
Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026

LB2102 demonstrated a manageable safety profile and encouraging clinical activity in solid tumors among heavily pretreated patients  Responses observed at higher dose levels of LB2102 with an ORR of...

LEGN : 27.93 (-16.68%)
Legend Biotech Conference Spotlights CARVYKTI’s Curative Potential, Earlier Use

Legend Biotech (NASDAQ:LEGN) used an investor and analyst event to highlight long-term data and physician perspectives supporting broader use of CARVYKTI, its BCMA-directed CAR T-cell therapy for multiple...

LEGN : 27.93 (-16.68%)
Legend Biotech Announces Presentations at ASCO 2026

Preliminary results from Phase 1 data for LB2102 to reinforce early evidence of activity in solid tumors in a rapid oral presentation New data from the CARTITUDE-4 study to highlight a cytogenetic...

LEGN : 27.93 (-16.68%)
Legend Biotech Q1 Earnings Call Highlights

Legend Biotech (NASDAQ:LEGN) reported sharply higher first-quarter 2026 sales for CARVYKTI, its CAR T therapy for multiple myeloma, as management said demand continued to move into earlier lines of treatment...

LEGN : 27.93 (-16.68%)
Legend Biotech Reports First Quarter 2026 Results and Recent Highlights

CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) net trade sales increased 62% versus first quarter of 2025 to approximately $597 million CARVYKTI ® now available across 18 global markets,...

LEGN : 27.93 (-16.68%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Average short term outlook on maintaining the current direction.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Legend Biotech Corporation is a clinical-stage biopharmaceutical company. It engaged in the discovery and development of novel cell therapies for oncology and other indications. The company's lead product consist LCAR-B38M/JNJ-4528, which are in clinical stage. Legend Biotech Corporation is based in...

See More

Key Turning Points

3rd Resistance Point 31.71
2nd Resistance Point 30.76
1st Resistance Point 29.34
Last Price 27.93
1st Support Level 26.97
2nd Support Level 26.02
3rd Support Level 24.60

See More

52-Week High 45.30
Fibonacci 61.8% 34.20
Fibonacci 50% 30.77
Last Price 27.93
Fibonacci 38.2% 27.34
52-Week Low 16.24

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.